selleck chem Registration and Sign Up Information | selleckchem

Post-Registration Data

We are still gathering data about this website

Validation

This site did not show evidence of storing passwords in plaintext.

This site does allow secured connections (https)

This site did show a clear way to unsubscribe from their emails

This site does verify your email address.

Membership Emails

Below is a sample of the emails you can expect to receive when signed up to selleck chem.

Picking out the Most Suitable ...
FDA Approved Monoclonal Antibo...
Check out New Inhibitor Librar...

Up-to-date Screening Libraries

● A collection of over 120,000 small molecules with validated biological and pharmacological activities

● Demonstrated by preclinical and clinical research, with numerous FDA-approved compounds

● Focused on over 200 targets that are part of more than 20 signaling pathways, including MAPK pathways

Screening Libaries

Cat. No.	Product Name	Number of Small Molecules
Clinical and FDA-approved Related:
L1300	FDA-approved Drug Library >>	2697 Compounds
L3800	FDA-approved & Passed Phase I Drug Library >>	2991 Compounds
L3900	Preclinical/Clinical Compound Library >>	2814 Compounds
L8000	FDA-approved Anticancer Drug Library >>	1567 Compounds
Bioactive Compound Libraries:
L1700	Bioactive Compound Library-I >>	7120Compounds
L1700-II	Bioactive Compound Library-II >>	5309 Compounds
L3600	Express-Pick Library >>	4208 Compounds
L5000	HTS Library for Drug Discovery >>	99040 Compounds
L8500	Phenotypic Screening Library >>	3751 Compounds
Inhibitor Related:
L1200	Kinase Inhibitor Library >>	1525 Compounds
L3500	Highly Selective Inhibitor Library >>	339 Compounds
L1100	Inhibitor Library >>	3456 Compounds
L2500	Protease Inhibitor Library >>	227 Compounds
L8100	Protein-protein Interaction Inhibitor Library >>	188 Compounds
L1800	Tyrosine Kinase Inhibitor Library >>	390 Compounds
Cell Death Related:
L3300	Apoptosis Compound Library >>	978 Compounds
L2600	Autophagy Compound Library >>	998 Compounds
L6400	Ferroptosis Compound Library >>	547 Compounds
L7400	Pyroptosis Compound Library >>	441 Compounds
Anti-infection and Antiviral Related:
L7200	Nucleoside Analogue Library >>	135 Compounds
L7000	Antiviral Compound Library >>	347Compounds
L3100	Anti-infection Compound Library >>	927 Compounds
L5300	Antibiotics compound Library >>	308 Compounds
By Disease:
L7100	Anti-cancer Compound Library >> (Verified by Broad Institute)	923 Compounds
L5900	Anti-alzheimer Disease Compound Library >>	486 Compounds
L2900	Anti-diabetic Compound Library >>	152 Compounds
L6200	Anti-Aging Compound Library >>	1503 Compounds
Neuronal and Immunology Related:
L4700	CNS-Penetrant Compound Library >>	307 Compounds
L4100	Immunology/Inflammation Compound Library >>	1834Compounds
L4000	Neuronal Signaling Compound Library >>	1093 Compounds
Metabolism Related:
L3700	Metabolism Compound Library >>	2024 Compounds
L4500	Human Endogenous Metabolite Compound Library >>	541 Compounds
Natural Product and Medicine Food Homology Related:
L1400	Natural Product Library >>	2266 Compounds
L7600	Natural Organic Compound Library >>	1127 Compounds
L8300	Traditional Chinese Medicine Library >>	1044 Compounds

Customize Your Library

You can Select:


Specific Compounds		Quantities		Plate Map		Format (solid or DMSO solution)

View this in web browser version.

Tel: +1-832-582-8158
Fax: +1-832-582-8590
Email: sales@selleckchem.com
Address: 14408 W Sylvanfield Drive, Houston, TX 77014 USA

Tel: +49-89-46148500
Fax: +49-89-461485022
Email: eu.info@selleckchem.com
Address: Karl-Schmid-Str. 14, 81829 Munich, Germany

View this email in your browser

This message was sent to @ by reply@selleckchemical.com

Unsubscribe | Manage Subscription | Forward Email | Report Abuse

Marketing, Houston, TX, 77014

Development Timeline on Therapeutic Antibodies

J Biomed Sci. 2020 Jan 2;27(1):1.
doi: 10.1186/s12929-019-0592-z

FDA-approved Monoclonal Antibody on the Market
FDA-approved Monoclonal Antibody on the Market

For research use only. Not for use in humans.

Antibody	Target	Format	Indication	Year of FDA Approval
Rituximab >>	CD20	Chimeric IgG1	Non-Hodgkin lymphoma	1997
Trastuzumab >>	HER2	Humanized IgG1	Breast cancer	1998
Alemtuzumab	CD52	Humanized IgG1	Chronic myeloid leukemia	2001
Adalimumab >>	TNFα	Human IgG1	Rheumatoid arthritis	2002
Ibritumomab	CD20	Murine IgG1	Non-Hodgkin lymphoma	2002
Cetuximab >>	EGFR	Chimeric IgG1	Colorectal cancer	2004
Bevacizumab >>	VEGF-A	Humanized IgG1	Colorectal cancer	2004
Natalizumab	ITGA4	Humanized IgG4	Multiple sclerosis	2004
Panitumumab	EGFR	Human IgG2	Colorectal cancer	2006
Ranibizumab	VEGF-A	Humanized IgG1 Fab	Macular degeneration	2006
Eculizumab	C5	Humanized IgG2/4	Paroxysmal nocturnal hemoglobinuria	2007
Certolizumab pegol	TNFα	Humanized Fab, pegylated	Crohn’s disease	2008
Ustekinumab	IL-12/23	Human IgG1	Psoriasis	2009
Canakinumab	IL-1β	Human IgG1	Muckle-Wells syndrome	2009
Golimumab	TNFα	Human IgG1	Rheumatoid and psoriatic arthritis, ankylosing spondylitis	2009
Ofatumumab	CD20	Human IgG1	Chronic lymphocytic leukemia	2009
Tocilizumab >>	IL-6R	Humanized IgG1	Rheumatoid arthritis	2010
Ipilimumab >>	CTLA-4	Human IgG1	Metastatic melanoma	2011
Brentuximab	CD30	Chimeric IgG1; ADC	Hodgkin lymphoma, systemic anaplastic large cell lymphoma	2011
Pertuzumab >>	HER2	Humanized IgG1	Breast Cancer	2012
Trastuzumab >>	HER2	Humanized IgG1; ADC	Breast cancer	2012
Obinutuzumab	CD20	Humanized IgG1 Glycoengineered	Chronic lymphocytic leukemia	2013
Siltuximab	IL-6	Chimeric IgG1	Castleman disease	2014
Ramucirumab	VEGFR2	Human IgG1	Gastric cancer	2014
Vedolizumab	α4β7 integrin	Humanized IgG1	Ulcerative colitis, Crohn disease	2014
Blinatumomab	CD19, CD3	Murine bispecific tandem scFv	Acute lymphoblastic leukemia	2014
Nivolumab >>	PD-1	Human IgG4	Melanoma, non-small cell lung cancer	2014
Pembrolizumab >>	PD-1	Humanized IgG4	Melanoma	2014
Necitumumab	EGFR	Human IgG1	Non-small cell lung cancer	2015
Dinutuximab	GD2	Chimeric IgG1	Neuroblastoma	2015
Secukinumab	IL-17α	Human IgG1	Psoriasis	2015
Mepolizumab	IL-5	Humanized IgG1	Severe eosinophilic asthma	2015
Daratumumab	CD38	Human IgG1	Multiple myeloma	2015
Elotuzumab	SLAMF7	Humanized IgG1	Multiple myeloma	2015
Ixekizumab	IL-17α	Humanized IgG4	Psoriasis	2016
Reslizumab	IL-5	Humanized IgG4	Asthma	2016
Olaratumab	PDGFRα	Human IgG1	Soft tissue sarcoma	2016
Atezolizumab >>	PD-L1	Humanized IgG1	Bladder cancer	2016
Obiltoxaximab	B.anthrasis PA	Chimeric IgG1	Prevention of inhalational anthrax	2016
Dupilumab	IL-4Rα	Human IgG4	Atopic dermatitis	2017
Sarilumab >>	IL-6R	Human IgG1	Rheumatoid arthritis	2017
Avelumab	PD-L1	Human IgG1	Merkel cell carcinoma	2017
Ocrelizumab	CD20	Humanized IgG1	Multiple sclerosis	2017
Benralizumab	IL-5Rα	Humanized IgG1	Asthma	2017
Durvalumab >>	PD-L1	Human IgG1	Bladder cancer	2017
Mogamulizumab	CCR4	Humanized IgG1	Mycosis fungoides or Sézary syndrome	2018
Tildrakizumab	IL-23 p19	Humanized IgG1	Plaque psoriasis	2018
Cemiplimab	PD-1	Human mAb	Cutaneous squamous cell carcinoma	2018
Emapalumab	IFNγ	Human IgG1	Primary hemophagocytic lymphohistiocytosis	2018
Fremanezumab	CGRP	Humanized IgG2	Migraine prevention	2018
Ibalizumab	CD4	Humanized IgG4	HIV infection	2018
Moxetumoma	CD22	Murine IgG1 dsFv	Hairy cell leukemia	2018
Risankizumab	IL-23 p19	Humanized IgG1	Plaque psoriasis	2019
Polatuzumab	CD79β	Humanized IgG1 ADC	Diffuse large B-cell lymphoma	2019
Brolucizumab	VEGF-A	Humanized scFv	Macular degeneration	2019

J Biomed Sci. 2020 Jan 2;27(1):1.
doi: 10.1186/s12929-019-0592-z

Approaches for Development of Therapeutic Antibodies
Approaches for Development of Therapeutic Antibodies

J Biomed Sci. 2020 Jan 2;27(1):1.
doi: 10.1186/s12929-019-0592-z

View this in web browser version.

Tel: +1-832-582-8158
Fax: +1-832-582-8590
Email: [email protected]
Address:14408 W Sylvanfield Drive, Houston, TX 77014 USA

Tel: +49-89-46148500
Fax: +49-89-461485022
Email: [email protected]
Address: Karl-Schmid-Str. 14, 81829 Munich, Germany

View this email in your browser

This message was sent to @ by reply@selleckchemical.com

Unsubscribe | Manage Subscription | Forward Email | Report Abuse

Marketing, Houston, TX, 77014

Up-to-date Screening Libraries

● A collection of over 120,000 small molecules with validated biological and pharmacological activities

● Demonstrated by preclinical and clinical research, with numerous FDA-approved compounds

● Focused on over 200 targets that are part of more than 20 signaling pathways, including MAPK pathways

Screening Libraries

Cat. No.	Product Name	Number of Small Molecules
New Libraries on Shelf:
L8500	Phenotypic Screening Library >>	3751 Compounds
L6100	HIF-1 Signaling Pathway Compound Library >>	447 Compounds
L8100	Protein-protein Interaction Inhibitor Library >>	188 Compounds
L6200	Anti-Aging Compound Library >>	1499 Compounds
L8200	Anti-parasitic Compound Library >>	171 Compounds
L8300	Traditional Chinese Medicine Library >>	1044 Compounds
Clinical and FDA-approved Related:
L1300	FDA-approved Drug Library >>	2697 Compounds
L3800	FDA-approved & Passed Phase I Drug Library >>	2991 Compounds
L3900	Preclinical/Clinical Compound Library >>	2814 Compounds
L8000	FDA-approved Anticancer Drug Library >>	1567 Compounds
Bioactive Compound Libraries:
L1700	Bioactive Compound Library-I >>	7120Compounds
L1700-II	Bioactive Compound Library-II >>	5309 Compounds
L3600	Express-Pick Library >>	4208 Compounds
L5000	HTS Library for Drug Discovery >>	99040 Compounds
Cell Death Related:
L3300	Apoptosis Compound Library >>	978 Compounds
L2600	Autophagy Compound Library >>	998 Compounds
By Disease:
L7100	Anti-cancer Compound Library >> (Verified by Broad Institute)	923 Compounds
L6200	Anti-Aging Compound Library >>	1503 Compounds
Neuronal and Immunology Related:
L4100	Immunology/Inflammation Compound Library >>	1834Compounds
L4000	Neuronal Signaling Compound Library >>	1093 Compounds
Metabolism Related:
L3700	Metabolism Compound Library >>	2024 Compounds
Natural Product and Medicine Food Homology Related:
L1400	Natural Product Library >>	2266 Compounds
L7600	Natural Organic Compound Library >>	1127 Compounds